Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -57.0x - -63.0x | -60.0x |
| Selected Fwd P/E Multiple | 3.6x - 4.0x | 3.8x |
| Fair Value | ₩40,171 - ₩44,400 | ₩42,285 |
| Upside | 2.6% - 13.4% | 8.0% |
| Benchmarks | - | Full Ticker |
| Oscotec Inc. | - | KOSDAQ:A039200 |
| Komipharm International Co., Ltd. | - | KOSDAQ:A041960 |
| Hanall Biopharma Co., Ltd. | - | KOSE:A009420 |
| ADBiotech Co., Ltd. | - | KOSDAQ:A179530 |
| WooGene B&G Co., Ltd | - | KOSDAQ:A018620 |
| Mezzion Pharma Co.,Ltd. | - | KOSDAQ:A140410 |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| A039200 | A041960 | A009420 | A179530 | A018620 | A140410 | |||
| KOSDAQ:A039200 | KOSDAQ:A041960 | KOSE:A009420 | KOSDAQ:A179530 | KOSDAQ:A018620 | KOSDAQ:A140410 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 103.6% | 429.6% | -151.4% | -177.7% | -341.0% | -53.0% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -361.4% | -17.6% | 7.9% | -36.4% | -5.1% | -80.4% | ||
| Prior Fiscal Year | -490.4% | -9.3% | 2.6% | -27.3% | -2.0% | -40.1% | ||
| Latest Fiscal Year | 2.6% | 22.3% | -1.3% | -71.4% | -9.4% | -226.2% | ||
| Latest Twelve Months | 2.6% | 22.3% | -1.3% | -71.4% | -9.4% | -226.2% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | -1209.6x | 46.6x | 406.9x | -9.2x | 17.3x | -86.0x | ||
| Price / LTM Sales | 30.8x | 6.9x | 10.3x | 1.8x | 0.5x | 136.4x | ||
| LTM P/E Ratio | 1193.4x | 31.1x | -792.8x | -2.6x | -4.9x | -60.3x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -792.8x | -2.6x | 1193.4x | |||||
| Historical LTM P/E Ratio | -310.4x | -59.9x | -14.1x | |||||
| Selected P/E Multiple | -57.0x | -60.0x | -63.0x | |||||
| (x) LTM Net Income | (19,477) | (19,477) | (19,477) | |||||
| (=) Equity Value | 1,111,028 | 1,169,503 | 1,227,978 | |||||
| (/) Shares Outstanding | 30.0 | 30.0 | 30.0 | |||||
| Implied Value Range | 37,025.21 | 38,973.90 | 40,922.60 | |||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 37,025.21 | 38,973.90 | 40,922.60 | 39,150.00 | ||||
| Upside / (Downside) | -5.4% | -0.4% | 4.5% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | A039200 | A041960 | A009420 | A179530 | A018620 | A140410 | |
| Value of Common Equity | 1,046,088 | 407,999 | 1,430,869 | 20,515 | 25,450 | 1,174,787 | |
| (/) Shares Outstanding | 38.2 | 69.7 | 50.7 | 11.4 | 28.9 | 30.0 | |
| Implied Stock Price | 27,350.00 | 5,850.00 | 28,200.00 | 1,806.00 | 881.00 | 39,150.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 27,350.00 | 5,850.00 | 28,200.00 | 1,806.00 | 881.00 | 39,150.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |